samedan logo
 
 
spacer
home > ebr > winter 2003 > cowpox to conjugates: trends in vaccines
PUBLICATIONS
European Biopharmaceutical Review

Cowpox to Conjugates: Trends in Vaccines

Vaccines are a group of products that include some of the oldest biological pharmaceutical entities. They are also an area where new techniques and manufacturing technologies are giving rise to significant growth. While eradication of some historic diseases has led to a lower need for prophylaxis, the resurgent threat of bioterrorism has given impetus to finding new and rapid methods for producing vaccines against a range of new and old threats, such as Anthrax.

Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Ian Sellick, Director of Marketing at Pall Life Sciences

Ian Sellick is Marketing Director with Pall Life Sciences, where he is responsible for the spectrum of membrane-based technologies for separations and purification, and processing systems based on those technologies. Ian has 20 years' experience in the separations industries, the last eight with Pall Corporation. He holds an Honours degree in Zoology (with Cell Biology and Pharmacology) from the University of Bristol, and has post-graduate research experience in mucin biochemistry, growth dynamics and polymorphic isozymes of fish. Ian has published a large number of articles and papers, including papers on separations for food and dairy derived products, as well as the Institute of Brewing's book on beer filtration. He speaks regularly at conferences on separations for the biotechnology industry.

spacer
Ian Sellick
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

BioPh Europe

5-7 October 2010, Paris, France

All companies and organisations dealing with the research and development of new treatment methods made through biotechnological processes or which are derived from or use live organisms will benefit from the mix of exhibition, seminars and 121 partnering meetings at BioPh. BioPh Europe 2010 at Paris Nord Villepinte will offer you unrivalled networking and commercial opportunities in the world of drug research and manufacturing. 
More info >>

 
News and Press Releases

Glycotope GMBH

Berlin, Germany – August 4, 2010 Glycotope GmbH, a leading glycobiology company, has received regulatory approval by German and Italian regulatory authorities for a Phase I study of Glycotope´s next generation antibody CetuGEX (GT-MAB 5.2-GEX) for the treatment of various solid cancers.
More info >>

 

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement